登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由天津医科大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07099274,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
At least one measurable target lesion confirmed by screening imaging per RECIST v1.1;
入选标准第 8 条
Histologically/cytologically confirmed fibrolamellar HCC, sarcomatoid HCC, cholangiocarcinoma, or mixed hepatocellular-cholangiocarcinoma;
入选标准第 12 条
Child-Pugh class A or class B (score ≤7) without hepatic encephalopathy history;
入选标准第 6 条
ECOG performance status 0-2;
入选标准第 5 条
Active HBV/HCV infection requires ongoing antiviral therapy; k.Fertile patients must use highly effective contraception with partners during treatment and ≥180 days post-last dose.
入选标准第 10 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07099274,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Comprehension and voluntary signing of the study's informed consent form; Age ≥18 years, any gender; Histologically or clinically confirmed hepatocellular carcinoma; Documented failure or intolerance to first-line therapy with PD-1/PD-L1 inhibitor plus bevacizumab; ECOG performance status 0-2; Child-Pugh class A or class B (score ≤7) without hepatic encephalopathy history; Life expectancy ≥3 months; At least one measurable target lesion confirmed by screening imaging per RECIST v1.1; Adequate organ and bone marrow function within 7 days prior to initial study treatment; Active HBV/HCV infection requires ongoing antiviral therapy; k.Fertile patients must use highly effective contraception with partners during treatment and ≥180 days post-last dose. Inability to comply with the study protocol or procedures; Histologically/cytologically confirmed fibrolamellar HCC, sarcomatoid HCC, cholangiocarcinoma, or mixed hepatocellular-cholangiocarcinoma; History of liver transplantation or planned transplantation; Presence of central nervous system metastases and/or leptomeningeal carcinomatosis; Baseline imaging showing Vp4 portal vein tumor thrombosis; Hypersensitivity to any study drug components or history of severe allergic reactions; Concurrent HBV and HCV co-infection; Clinically significant ascites requiring intervention during screening; Concurrent use of other investigational drugs or participation in another clinical trial within 4 weeks prior to enrollment; Esophageal/gastric variceal bleeding due to portal hypertension within 6 months before treatment initiation, or high-risk varices on endoscopy within 3 months; Current interstitial lung disease (ILD), history of steroid-required ILD, or other pulmonary fibrosis/organizing pneumonia affecting immune-related pulmonary toxicity assessment; Uncontrolled hypertension (SBP≥160 mmHg and/or DBP≥100 mmHg despite medication), coronary artery disease, arrhythmias, or heart failure (NYHA Class ≥II); Uncontrolled clinically significant infections requiring IV antimicrobial therapy; Proteinuria ≥2+ (≥1.0g/24h); History of hemorrhagic tendency regardless of severity within 2 months prior to enrollment; Arterial/venous thromboembolic events within 12 months before treatment initiation (e.g., cerebrovascular accident including TIA); Acute myocardial infarction, acute coronary syndrome, or CABG within 6 months before treatment; Unhealed fractures or chronic non-healing wounds; Coagulopathy, bleeding diathesis, or current therapeutic anticoagulation; Other malignancies within 5 years except curatively resected basal/squamous cell skin carcinoma or cervical carcinoma in situ; Active autoimmune disease or autoimmune disease history requiring immunosuppression within 4 weeks prior to enrollment; Prior allogeneic bone marrow or solid organ transplantation; Investigator assessment of ineligibility based on medical/safety reasons.排除标准:Exclusion Criteria:
引自 ClinicalTrials.gov, NCT07099274, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07099274,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。